Last updated on January 2017

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma


Brief description of study

The purpose of this study is to compare 2 years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.

Detailed Study Description

This study is designed to compare 2 years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma. Primary Outcome Measure: Disease-free survival between Icotinib group and placebo group. Secondary Outcome Measures: Overall survival between Icotinib group and placebo group. Lung cancer symptoms and health-related quality of life (HRQoL) . Number of participants with adverse events.

Clinical Study Identifier: NCT02125240

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Hui Li, MD

Beijing Chaoyang Hospital
Beijing, China
  Connect »

Gang Cheng, MD

Beijing Hospital
Beijing, China
  Connect »

Li Zhang, MD

Beijing Union Medical College Hospital
Beijing, China
  Connect »

Yuan-Kai Shi, MD

Cancer Hospital, Chinese Academy of Medical Science
Beijing, China
  Connect »

De-Ruo Liu, MD

China-japan friendship hospital in Beijing
Beijing, China
  Connect »

Jian Li, MD

Peking University First Hospital
Beijing, China
  Connect »

Jun Wang, MD

Peking University People's Hospital
Beijing, China
  Connect »

Wen-Hua Xiao, MD

304 Hospital of PLA
Beijing, China
  Connect »

Xiu-Yi Zhi, MD

Xuanwu Hospital, Capital Medical University
Beijing, China
  Connect »

Yi Hu, MD

People's Liberation Army General Hospital (301 Hospital)
Beijing, China
  Connect »

Shu-Cai Zhang, MD

Capital Medical University, Beijing Chest Hospital
Beijing, China
  Connect »